[go: up one dir, main page]

WO2016193977A3 - Méthodes de prévision de l'hépatotoxicité - Google Patents

Méthodes de prévision de l'hépatotoxicité Download PDF

Info

Publication number
WO2016193977A3
WO2016193977A3 PCT/IL2016/050566 IL2016050566W WO2016193977A3 WO 2016193977 A3 WO2016193977 A3 WO 2016193977A3 IL 2016050566 W IL2016050566 W IL 2016050566W WO 2016193977 A3 WO2016193977 A3 WO 2016193977A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
genes
panel
methods
hepatotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2016/050566
Other languages
English (en)
Other versions
WO2016193977A2 (fr
Inventor
Ganit YARDEN
Assaf Wool
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen Ltd
Neviah Genomics Ltd
Original Assignee
Compugen Ltd
Neviah Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd, Neviah Genomics Ltd filed Critical Compugen Ltd
Publication of WO2016193977A2 publication Critical patent/WO2016193977A2/fr
Publication of WO2016193977A3 publication Critical patent/WO2016193977A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de prévision de l'hépatotoxicité d'un composé par la fourniture d'un système de culture d'hépatocytes in vitro capable d'exprimer un panel de gènes, la culture pouvant être incubée avec le composé ou les composés à analyser, et le niveau d'expression du panel de gènes pouvant être mesuré. En comparant le niveau d'expression du panel de gènes dans le système de culture exposé au(x) composé(s) analysé(s) et l'expression génique du même panel de gènes dans un système de culture de contrôle, l'hépatotoxicité du composé ou des composés peut être prédite.
PCT/IL2016/050566 2015-06-03 2016-06-02 Méthodes de prévision de l'hépatotoxicité Ceased WO2016193977A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL239188A IL239188A0 (en) 2015-06-03 2015-06-03 Methods for predicting hepatotoxicity
IL239188 2015-06-03

Publications (2)

Publication Number Publication Date
WO2016193977A2 WO2016193977A2 (fr) 2016-12-08
WO2016193977A3 true WO2016193977A3 (fr) 2017-03-16

Family

ID=55022871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2016/050566 Ceased WO2016193977A2 (fr) 2015-06-03 2016-06-02 Méthodes de prévision de l'hépatotoxicité

Country Status (2)

Country Link
IL (1) IL239188A0 (fr)
WO (1) WO2016193977A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237015A1 (fr) * 2018-06-08 2019-12-12 The Trustees Of Columbia University In The City Of New York Procédés et systèmes de prédiction de taux de réussite d'essais cliniques
CN110054674B (zh) * 2019-03-07 2022-08-05 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap2-19及应用
CN110054688B (zh) * 2019-03-07 2020-10-27 深圳市龙华区人民医院 一种抗ttc36单克隆抗体及其应用
CN110054676B (zh) * 2019-03-07 2022-08-02 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap3-5及应用
CN110003320A (zh) * 2019-03-22 2019-07-12 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体bp1-7及应用
CN110517790B (zh) * 2019-06-24 2023-06-09 江苏大学 基于深度学习和基因表达数据的化合物肝毒性早期预测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005547A1 (en) * 2002-03-14 2004-01-08 Franziska Boess Biomarkers and expression profiles for toxicology

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005547A1 (en) * 2002-03-14 2004-01-08 Franziska Boess Biomarkers and expression profiles for toxicology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HRACH J ET AL: "Development of anliver toxicity prediction model based on longer term primary rat hepatocyte culture", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 206, no. 2, 14 July 2011 (2011-07-14), pages 189 - 196, XP028276119, ISSN: 0378-4274, [retrieved on 20110723], DOI: 10.1016/J.TOXLET.2011.07.012 *
JENS HRACH: "Toxicogenomic approaches for the prediction of hepatotoxicity in vitro", 1 January 2009 (2009-01-01), pages 1 - 226, XP055313014, Retrieved from the Internet <URL:http://archiv.ub.uni-heidelberg.de/volltextserver/9204/1/Dissertation_Jens_Hrach.pdf> [retrieved on 20161021] *
WARING J F ET AL: "MICROARRAY ANALYSIS OF HEPATOTOXINS IN VITRO REVEALS A CORRELATION BETWEEN GENE EXPRESSION PROFILES AND MECHANISMS OF TOXICITY", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 120, no. 1-03, 1 March 2001 (2001-03-01), pages 359 - 368, XP001156936, ISSN: 0378-4274, DOI: 10.1016/S0378-4274(01)00267-3 *

Also Published As

Publication number Publication date
IL239188A0 (en) 2015-11-30
WO2016193977A2 (fr) 2016-12-08

Similar Documents

Publication Publication Date Title
WO2016193977A3 (fr) Méthodes de prévision de l&#39;hépatotoxicité
SG11202001916TA (en) Systems, methods and hydrogels for cell culture and analysis
WO2015159293A3 (fr) Procédé et kit permettant de déterminer l&#39;origine tissulaire ou cellulaire de l&#39;adn
EP3267962A4 (fr) Système, procédé et dispositif de culture automatisée à haut débit d&#39;organismes génétiquement modifiés
EP3161127A4 (fr) Cellules souches limbiques de mammifères en culture, leurs méthodes de production et leurs utilisations
EP3222718A4 (fr) Procédé pour le knock-in d&#39;adn dans une région cible d&#39;un génome mammifère et cellule
WO2015188106A3 (fr) Méthodes de culture par perfusion et utilisations desdites méthodes
EP3222744A4 (fr) Feuille d&#39;acier épaisse, haute dureté, haute ténacité ayant une excellente uniformité de matière et son procédé de fabrication
EP3467095A4 (fr) Récipient de culture cellulaire
NZ730124A (en) A method of predicting risk of recurrence of cancer
EP3874023A4 (fr) Procédé de culture cellulaire par perfusion intensifiée avec récolte continue et sans purge cellulaire
WO2016094583A3 (fr) Biomarqueurs de la qualité d&#39;un ovocyte
WO2014130864A3 (fr) Procédés de culture par perfusion de microporteurs et leurs utilisations
WO2014130872A3 (fr) Procédés de culture par perfusion de microporteurs et leurs utilisations
EP3749335A4 (fr) Bioréacteurs permettant la perfusion
EP3255137A4 (fr) Système de culture cellulaire
EP3653696A4 (fr) Récipient de culture cellulaire
PH12016502381A1 (en) Gene expression system
EP3964560A4 (fr) Système de culture cellulaire
WO2015003160A3 (fr) Hépatocytes en co-culture et leurs utilisations
EP3162891A4 (fr) Procédé pour promouvoir la différenciation de cellules en culture et promoteur de différenciation de cellules en culture
MX2017016136A (es) Sistema de control de plagas.
GB201722186D0 (en) Methods and systems for the culture of cells at liquid-liquid interfaces
EP3270934A4 (fr) Micro-supports, matrices et échafaudages pour la culture de cellules de mammifère et procédés de fabrication
MA53557A (fr) Procédés de culture cellulaire continue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16774554

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.04.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16774554

Country of ref document: EP

Kind code of ref document: A2